Next Article in Journal
Hypertension Assessment Using Photoplethysmography: A Risk Stratification Approach
Next Article in Special Issue
Evidence for a Common Genetic Origin of Classic and Milder Adult-Onset Forms of Isolated Hypogonadotropic Hypogonadism
Previous Article in Journal
The Mediating Role of Perceived Stress in the Relationship of Self-Efficacy and Work Engagement in Nurses
Previous Article in Special Issue
Do Androgens Modulate the Pathophysiological Pathways of Inflammation? Appraising the Contemporary Evidence
Open AccessReview

Testosterone Therapy, Thrombophilia, Venous Thromboembolism, and Thrombotic Events

Cholesterol, Metabolism, and Thrombosis Center, Cincinnati Ohio, OH 45220, USA
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(1), 11; https://doi.org/10.3390/jcm8010011
Received: 3 December 2018 / Revised: 11 December 2018 / Accepted: 18 December 2018 / Published: 21 December 2018
(This article belongs to the Special Issue Testosterone and Men’s Health: From Evidence to Clinical Practice)
In our sequential studies of 67 and 21 patients, testosterone therapy (TT) interacted with thrombophilia–hypofibrinolysis, leading to venous thromboembolism (VTE). Compared to 111 VTE controls not taking TT (VTE-no TT), the 67 and 21 cases were more likely (p < 0.05 for all) to have Factor V Leiden (FVL) heterogeneity (24% and 33% vs. 12%), the lupus anticoagulant (14% and 33% vs. 4%), and high lipoprotein(a) (33% vs. 13%, n = 21). After a first VTE and continuing TT, 11 thrombophilic cases had a second VTE despite adequate anticoagulation, 6 of whom, still anticoagulated, had a third VTE. The greatest density of thrombotic events was at three months after starting TT, with a rapid decline by 10 months. From <1 to 8 months after starting TT, 65% of VTE occurred, which may reflect TT-induced depletion of susceptible thrombophilic patients, leaving a winnowed residual group with fewer VTE events despite the continuation of TT. Before starting TT, we suggest screening for FVL, lipoprotein(a), and the lupus anticoagulant to identify patients at increased VTE risk, with an adverse risk-to-benefit ratio for TT. We suggest that TT should not be started in patients with known thrombophilia–hypofibrinolysis, and should not be continued after a first VTE. When TT is given to patients with thrombophilia–hypofibrinolysis, VTE may occur and then recur despite adequate anticoagulation. View Full-Text
Keywords: testosterone; thrombophilia; hypofibrinolysis; venous thromboembolism (VTE); Factor V Leiden heterozygosity; lupus anticoagulant; lipoprotein (a); thrombosis testosterone; thrombophilia; hypofibrinolysis; venous thromboembolism (VTE); Factor V Leiden heterozygosity; lupus anticoagulant; lipoprotein (a); thrombosis
Show Figures

Figure 1

MDPI and ACS Style

Glueck, C.J.; Goldenberg, N.; Wang, P. Testosterone Therapy, Thrombophilia, Venous Thromboembolism, and Thrombotic Events. J. Clin. Med. 2019, 8, 11. https://doi.org/10.3390/jcm8010011

AMA Style

Glueck CJ, Goldenberg N, Wang P. Testosterone Therapy, Thrombophilia, Venous Thromboembolism, and Thrombotic Events. Journal of Clinical Medicine. 2019; 8(1):11. https://doi.org/10.3390/jcm8010011

Chicago/Turabian Style

Glueck, Charles J.; Goldenberg, Naila; Wang, Ping. 2019. "Testosterone Therapy, Thrombophilia, Venous Thromboembolism, and Thrombotic Events" J. Clin. Med. 8, no. 1: 11. https://doi.org/10.3390/jcm8010011

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop